The Food and Drug Administration (FDA) has granted approval for a request made by DreaMed regarding their artificial intelligence-enabled diabetic software, which is exclusively meant for the providers, who are managing Type 1 diabetes patients.
As ImmusanT initiates the process to develop its treatment regimens for celiac disease and Type 1 diabetes, the company has fast-paced its hiring activity by bringing on board Ken Truitt M.D. Daiichi Sankyo’s SVP for internal medicine therapeutics as its new Chief Medical Officer.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.